Journalartikel

Clinical impact of a novel three-dimensional electrocardiographic imaging for non-invasive mapping of ventricular arrhythmias-a prospective randomized trial


AutorenlisteErkapic, Damir; Greiss, Harald; Pajitnev, Dmitri; Zaltsberg, Sergey; Deubner, Nicolas; Berkowitsch, Alexander; Moellman, Susanne; Sperzel, Johannes; Rolf, Andreas; Schmitt, Joern; Hamm, Christian W.; Kuniss, Malte; Neumann, Thomas

Jahr der Veröffentlichung2015

Seiten591-597

ZeitschriftEP Europace

Bandnummer17

Heftnummer4

ISSN1099-5129

eISSN1532-2092

Open Access StatusBronze

DOI Linkhttps://doi.org/10.1093/europace/euu282

VerlagOxford University Press


Abstract

Aims ECVUE (TM) technology, a novel, three-dimensional, non-invasive mapping system, offers a unique arrhythmia characterization and localization. We sought to evaluate the clinical impact of this system in routine clinical mapping and ablation of ventricular arrhythmias (VAs).

Methods and results Patients with monomorphic premature ventricular contractions with or without monomorphic ventricular tachycardia were enrolled prospectively and randomized into two groups: ventricular ectopy localization using either 12-lead electrocardiogram (ECG) algorithms or with ECVUE (TM), followed by conventional guided ablation. Forty-two patients were enrolled in the study. The ECVUE (TM) system accurately identified both the chamber and sub-localized the VA origin in 20 of 21 (95.2%) patients. In contrast, using 12-lead ECG algorithms, the chamber was accurately diagnosed in 16 of 21 (76.2%) patients, while the arrhythmia origin in only 8 of 21 (38.1%), (P = 0.001 vs. ECVUE (TM)). Acute success in ablation was achieved in all patients. Regarding the number of radiofrequency-energy applications (in total 2 vs. 4, P = 0.005) in the ECVUE (TM) arm, ablation was more precise than the ECG group which used standard of care activation and pace mapping-guided ablation. Three months success in ablation was 95.2% for the ECVUE (TM) and 100% for the ECG group (P = ns). Time to ablation was 35.3 min in the conventional arm and 24.4 min in ECVUE Group, (P = 0.035). The X-ray radiation exposure was 3.21 vs. 0.39 mSv, P = 0.001 for the ECVUE (TM) group and ECG group.

Conclusion ECVUE (TM) technology offers a clinically useful tool to map VAs with high accuracy and more targeted ablations superior to the body surface ECG but had significantly higher radiation exposure due to computed tomography scan.




Zitierstile

Harvard-ZitierstilErkapic, D., Greiss, H., Pajitnev, D., Zaltsberg, S., Deubner, N., Berkowitsch, A., et al. (2015) Clinical impact of a novel three-dimensional electrocardiographic imaging for non-invasive mapping of ventricular arrhythmias-a prospective randomized trial, EP Europace, 17(4), pp. 591-597. https://doi.org/10.1093/europace/euu282

APA-ZitierstilErkapic, D., Greiss, H., Pajitnev, D., Zaltsberg, S., Deubner, N., Berkowitsch, A., Moellman, S., Sperzel, J., Rolf, A., Schmitt, J., Hamm, C., Kuniss, M., & Neumann, T. (2015). Clinical impact of a novel three-dimensional electrocardiographic imaging for non-invasive mapping of ventricular arrhythmias-a prospective randomized trial. EP Europace. 17(4), 591-597. https://doi.org/10.1093/europace/euu282



Schlagwörter


ABLATIONElectrocardiographic mappingelectrophysiologyGUIDE ABLATIONNon-invasive 3-D mappingOUTFLOW-TRACTPremature ventricular contractionVentricular arrhythmia


Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-10-06 um 10:29